See whether Helium helps you make better-informed decisions. Try every Pro Trader feature for 30 days. No credit card required.
Try every Pro Trader feature for 30 days. No credit card required.
April 30, 2026 · 0 shares
Investor-focused, optimism-driven bias leans bullish toward Phathom's VOQUEZNA strategy, foregrounding strong Q1 metrics, expanding gastroenterology sales, and reaffirmed 2026 guidance while acknowledging competition and risks, using management projections and market-share data as credibility anchors.
Phathom's Q1 2026 earnings call transcript highlights strong quarterly revenue growth, a significant expansion of gastroenterology-focused sales activity, and reaffirmed 2026 guidance, while detailing NBRx/NBRx shares, patient persistence metrics, and competitive dynamics (notably Tegoprazan) alongside near-term EoE Phase II data timelines and potential future expansion into primary care for VOQUEZNA.
I rely on the provided transcript; no external data; potential source bias.
2026 © Helium Trades
Privacy Policy & Disclosure
* Disclaimer: Nothing on this website constitutes investment advice, performance data or any recommendation that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. Helium Trades is not responsible in any way for the accuracy
of any model predictions or price data. Any mention of a particular security and related prediction data is not a recommendation to buy or sell that security. Investments in securities involve the risk of loss. Past performance is no guarantee of future results. Helium Trades is not responsible for any of your investment decisions,
you should consult a financial expert before engaging in any transaction.
